web analytics
Pubblicità

di Giancarlo Nicoli

Stereotaxis Reports 26% Third Quarter 2009 Revenue Growth

Filed Under Stereotaxis | Comments Off on Stereotaxis Reports 26% Third Quarter 2009 Revenue Growth

Stereotaxis Reports 26% Third Quarter 2009 Revenue Growth

Revenue of $13.3 Million; Recurring Revenue Grows 45%; Gross Margin Increases to 68% of Revenue; Operating Expenses Decline 18% from Prior Year

ST. LOUIS, Nov. 5 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS) today reported strong revenue growth, a significant increase in the gross margin, lower operating expenses and a significant reduction in the net loss for both the quarter and the nine month period ended September 30, 2009. Revenue for the recent third quarter totaled $13.3 million, an increase of 26% over $10.6 million for the 2008 third quarter. During the quarter, the Company recognized revenue on six Niobe® Magnetic Navigation Systems and seven Odyssey(TM) systems totaling $8.7 million. Disposables, services and accessories revenue reached a record $4.6 million, a 45% increase from the third quarter of 2008. Gross profit margin was 68% compared with 65% in the third quarter of 2008. Operating expenses declined 18% from the third quarter last year to $13.2 million.

For the first nine months of 2009, revenue grew 31% to $37.1 million compared with $28.2 million in the first nine months of 2008. Recurring revenue grew 56% from $8.6 million to $13.4 million and gross margin increased 37% to $24.7 million, or 67% of sales. Operating expenses decreased 19%, resulting in a 48% reduction in the operating loss to $18.0 million for the first nine months of 2009 compared with a $34.6 million operating loss in the same period in 2008.

Michael P. Kaminski, President and Chief Executive Officer, said, “The third quarter financial results reflect a solid improvement in our Company’s march to breakeven. We remain focused on driving revenue growth and strong margins while controlling operating expenses, resulting in a significant reduction in our cash burn to $3.5 million. We are particularly excited about the introduction of the Odyssey platform for non-magnetic labs as seen by the first multiple system order for non-magnetic labs in September. There is tremendous interest in the Odyssey and Cinema platform driven by increased market awareness and recognition of the system value. By consolidating many diverse sources of diagnostic and other information into a single manageable format, Odyssey offers improved procedure efficiency, enhanced archiving and a unique opportunity to network labs and sites together for educational and consulting purposes, creating a platform for improved quality of care. We have experienced significant market interest in this platform and anticipate it becoming a third leg to our revenue growth in 2010.”

“We are pleased with the third quarter recurring revenue of $4.6 million and the 45% growth over prior year but recognize that the challenge of driving clinical adoption is a process focused on moving the market to a new standard of care. We will continue to shift more resources into this important initiative to maximize our adoption at existing sites and to support the growth of the installed base.”

“During the quarter, we generated $6.3 million of new capital orders, up from $5.0 million in the second quarter. We are encouraged by the increase in new orders, which along with our backlog, positions us well for continued growth. Lastly, with the infusion of $28 million in net proceeds from our recent capital raise and our incremental improvement in cash burn, we believe the Company is positioned well to execute its growth plan and strategy in 2010 and beyond,” Mr. Kaminski concluded.

Third Quarter 2009 Financial Performance

Gross margin for the quarter was $9.0 million, or 68% of revenue, compared with $6.9 million, or 65% of revenue, in the third quarter of 2008. Third quarter operating expenses decreased 18% to $13.2 million from $16.1 million in the third quarter of 2008.

The operating loss in the third quarter decreased significantly to $(4.2) million compared with $(9.2) million in the prior year. The Company reported a net loss for the third quarter of 2009 of $(5.8) million, or $(0.14) per share. This compares with a net loss for the third quarter of 2008 of $(10.1) million, or $(0.28) per share. The weighted average shares for the recent third quarter totaled 42.0 million compared with 36.6 million in the third quarter of last year. The increase was due in large part to the issuance of 4.4 million shares as part of two concurrent private placements of stock completed in December 2008.

Cash used in operations was $3.5 million for the third quarter of 2009 compared with $5.5 million in the third quarter of 2008. Cash and equivalents at September 30, 2009 totaled $12.0 million, compared with $30.4 million at December 31, 2008. Total debt was $30.8 million, including $16.2 million drawn against the Company’s $25 million line of credit. As previously disclosed, in October 2009 the Company received a commitment to expand its line of credit from $25 million to $30 million and to extend the maturity date from March 31, 2010 to March 31, 2011.

On October 15, 2009, the Company completed a public stock offering, issuing a total of 7,475,000 shares of common stock, including the exercise of the underwriter’s over-allotment. The transaction was priced at $4.00 per share, representing gross proceeds of $29.9 million. Net of transaction costs, Stereotaxis received approximately $28 million in cash. This transaction will be reflected in the fourth quarter and year-end financial statements.

2009 Financial Guidance

The Company reiterates its outlook for 2009 as follows:

    --  Total revenue for 2009 is expected to exceed 2008 revenue.
    --  Gross margins above 65%.

    --  Operating expenses are now expected to be below $60 million for the full
        year 2009.

Conference Call Information

The Company has scheduled a conference call for 8:30 a.m. Eastern Time today to discuss its financial results for the third quarter. To access the conference call, please dial (877) 941-8631. International participants can call (480) 629-9822. An audio replay of the call will be available for seven days following the call at (800) 406-7325 for U.S. callers or (303) 590-3030 for those calling outside the U.S. The password required to access the replay is 4171622#. The call will also be available on the Internet live and for 90 days thereafter at the following URL:

http://www.videonewswire.com/event.asp?id=63211

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

                                    STEREOTAXIS, INC.
                                 STATEMENTS OF OPERATIONS
                                       (Unaudited)

                           Three Months Ended          Nine Months Ended
                              September 30,              September 30,
                           ------------------          -----------------
                           2009          2008          2009         2008
                           ----          ----          ----         ----
    Revenue
       System         $8,671,302    $7,365,480   $23,694,613   $19,641,188
       Disposables,
        service and
        accessories    4,619,391     3,186,169    13,373,484     8,597,503
                       ---------     ---------    ----------     ---------
    Total revenue     13,290,693    10,551,649    37,068,097    28,238,691

    Cost of revenue
       System          3,474,492     3,098,477     9,250,005     8,822,745
       Disposables,
        service and
        accessories      811,089       543,071     3,162,142     1,427,501
                         -------       -------     ---------     ---------
    Total cost of
     revenue           4,285,581     3,641,548    12,412,147    10,250,246

    Gross margin       9,005,112     6,910,101    24,655,950    17,988,445

    Operating expenses:
     Research and
      development      3,302,008     4,380,466    10,247,877    13,861,339
     Sales and
      marketing        6,290,814     7,012,264    21,424,796    23,297,003
     General and
      administration   3,654,207     4,719,779    11,006,981    15,458,115
                       ---------     ---------    ----------    ----------
    Total operating
     expenses         13,247,029    16,112,509    42,679,654    52,616,457
                      ----------    ----------    ----------    ----------
    Operating loss    (4,241,917)   (9,202,408)  (18,023,704)  (34,628,012)
    Other
    income/(expense)    (489,139)            -        66,507             -
    Interest income        2,721        33,711        34,069       165,665
    Interest
     expense          (1,085,408)     (904,428)   (2,860,479)   (1,931,606)
                     -----------      --------   -----------   -----------
    Net loss         $(5,813,743) $(10,073,125) $(20,783,607) $(36,393,953)
                     ===========  ============  ============  ============

     Net loss per
      common share:
        Basic and
         diluted          $(0.14)       $(0.28)       $(0.50)       $(1.00)
                          ======        ======        ======        ======

    Weighted average
     shares used in
     computing net
     loss per common
     share:
      Basic and
       diluted        41,985,315    36,612,877    41,648,104    36,541,593
                      ==========    ==========    ==========    ==========
                                      STEREOTAXIS, INC.
                                       BALANCE SHEETS

                                               September 30,  December 31,
                                                     2009          2008
                                                     ----          ----
                                                (Unaudited)
    Assets
    Current Assets:
     Cash and cash equivalents                  $12,012,659   $30,355,657
     Accounts receivable, net of allowance
      of $265,208 and $328,307 in 2009 and
      2008, respectively                         11,547,727     9,739,008
     Current portion of long-term receivables       340,333       197,351
     Inventories                                  6,979,759     8,086,956
     Prepaid expenses and other current
      assets                                      3,149,122     2,966,510
                                                  ---------     ---------
    Total current assets                         34,029,600    51,345,482
    Property and equipment, net                   5,106,215     6,420,600
    Intangible assets                             1,177,778     1,277,778
    Long-term Receivables                           142,723       298,123
    Other assets                                     27,162        98,382
                                                     ------        ------
    Total assets                                $40,483,478   $59,440,365
                                                ===========   ===========

    Liabilities and stockholders' equity
    Current liabilities:
       Current maturities of long-term debt      $8,734,824    $3,901,491
       Accounts payable                           4,084,037     4,561,928
       Accrued liabilities                        7,962,313     9,873,818
       Deferred contract revenue                  6,895,840     9,676,339
       Warrants                                   4,988,084             -
                                                  ---------           ---
    Total current liabilities                    32,665,098    28,013,576

    Long term debt, less current maturities      22,057,304    25,271,547
    Long term deferred contract revenue           1,014,592     1,225,656
    Other liabilities                                12,963       158,905

    Stockholders' equity:
       Preferred stock, par value $0.001;
        10,000,000 shares authorized at 2009
        and 2008; none outstanding at 2009
        and 2008                                          -             -
       Common stock, par value $0.001;
        100,000,000 shares authorized at 2009
        and 2008; 42,783,451 and 42,049,792
        issued at 2009 and 2008, respectively        42,783        42,050
       Additional paid-in capital               301,638,671   300,892,957
       Treasury stock, 40,151 shares at 2009
        and 2008                                   (205,999)     (205,999)
       Accumulated deficit                     (316,741,934) (295,958,327)
                                               ------------  ------------
    Total stockholders' equity                  (15,266,479)    4,770,681
                                                -----------     ---------
    Total liabilities and stockholders'
     equity                                     $40,483,478   $59,440,365
                                                ===========   ===========

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Showcases Interventional Value of Magnetic Navigation at TCT 2009

Filed Under Stereotaxis | Comments Off on Stereotaxis Showcases Interventional Value of Magnetic Navigation at TCT 2009

Stereotaxis Showcases Interventional Value of Magnetic Navigation at TCT 2009

ST. LOUIS, Sept. 24 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS) is showcasing the value of its technologies for interventional procedures at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Francisco this week. Stereotaxis pioneered remote magnetic navigation in electrophysiology and clinicians have repeatedly demonstrated the value of its technologies in the treatment of cardiac arrhythmias. More than 23,000 cases have been performed with the Magnetic Navigation System, and this clinical experience includes many compelling interventional procedures. In the cath lab as well as the EP lab, Stereotaxis’ computer-controlled devices, integrated information systems and advanced networking tools deliver opportunities for hospitals and clinicians to simplify the treatment of complex cases and ultimately aim for enhanced patient care and improved outcomes.

On Monday, September 21, Dr. Gurpreet S. Sandhu of the Mayo Clinic presented data from his use of Stereotaxis’ Magnetic Navigation System to treat chronic total occlusions. In his presentation “Beyond Guidewires: What Novel Technologies Help Today?” Dr. Sandhu highlighted the value of the Niobe system in the treatment of failed PCIs . Additionally, Dr. Jeffrey Moses of Columbia University Medical Center presented a live case in which he used the Stereotaxis three-dimensional vessel reconstruction to assist in the treatment of a chronic total occlusion in a patient who had previously undergone open heart surgery.

“Our Niobe System has been used to perform more procedures across the broadest range of cardiovascular applications than any other remote magnetic, robotic or mechanical navigation system presently available,” said Michael P. Kaminski, Stereotaxis President and CEO. “In addition to its widespread adoption in EP labs, the Niobe System has been used in the treatment of patients with congenital heart defects and peripheral vascular occlusive disease, and we are very excited about the opportunities we see to extend the value of our magnetic navigation and information management technologies into these and other potential cardio-vascular applications.”

At its TCT booth #600, Stereotaxis is showcasing its Pegasus(TM) Magnetic Guidewires and Odyssey(TM) System.

Pegasus Magnetic Guidewires

Stereotaxis recently introduced the Pegasus family of magnetically steerable guidewires. Pegasus is a blended stainless steel and Nitinol(TM) wire that provides exceptional and accurate omni-directional distal tip control. Its clinical advantages include excellent torque control and tip durability; optimal shaft support and device deliverability; and nearly effortless advancement through stenotic and tortuous vessel segments.

The Odyssey System

The Odyssey information backbone will be showcased by demonstrating the new Odyssey QuadHD ultra high resolution display and Odyssey Cinema, which synchronizes and archives lab data and can share a fully integrated view of a procedure with any laptop in the world on a high speed internet connection. This Odyssey portfolio is now designed to integrate standard labs, allowing all labs within a department to leverage the capabilities of remote lab viewing, recording and collaboration.

TCT is being held at the Moscone Center in San Francisco from September 21 to 25, 2009. For more information on Stereotaxis, please visit www.stereotaxis.com.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.

About Forward Looking Statements

This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center Orders 4 Odyssey Systems

Filed Under Stereotaxis | Comments Off on Texas Cardiac Arrhythmia Institute at St. David’s Medical Center Orders 4 Odyssey Systems

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center Orders 4 Odyssey Systems

Largest Single Odyssey Order to Date

ST. LOUIS, Sept. 15 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS), announced that the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas ordered four Odyssey(TM) systems. One will manage its Niobe((R)) Remote Magnetic Navigation electrophysiology lab and the other three will manage its standard, non-Niobe EP labs. All four systems will utilize an Odyssey Cinema server to record synchronized procedure data and share this information via the Internet anywhere in the world.

Odyssey Cinema synchronizes the data from multiple interventional lab systems and includes a powerful archiving capability to instantly store and replay an integrated view of entire procedures or segments of procedures. The solution also allows physicians to collaborate with high-definition views of live or recorded procedures from multiple points in the network of installed Odyssey systems, providing a significant new tool for clinical collaboration, remote consultation, and educational training. There are currently more than 60 Odyssey systems ordered to date.

“Our vision is to use Odyssey to significantly accelerate the advancement of electrophysiology worldwide,” said Andrea Natale, M.D., F.A.C.C., F.H.R.S., and Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. “With Odyssey, we have the technology to create unprecedented educational programs by sharing live cases over the network and by replaying best practices in interactive forums. Our connection to other centers on the Odyssey network will allow us to collaborate from Austin with other experts on a global basis without traveling. This creates a new standard for the practice of electrophysiology, unleashing new opportunities by allowing hospitals to have a powerful marketing tool and enabling patients on the Odyssey network to receive enhanced care around the world.”

The Texas Cardiac Arrhythmia Institute at St. David’s Medical Center will utilize the Odyssey network to connect with specific facilities around the world. Deliveries of the Odyssey systems to manage the standard EP labs will begin in the fourth quarter.

“This is the largest Odyssey order to date, and we are particularly excited by this opportunity to transform the EP department at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center,” said Michael P. Kaminski, Stereotaxis President and CEO. “We developed Odyssey to standardize data integration and management for all interventional labs and provide access to the live and recorded procedure information where and when it is needed. Through its proprietary data compression technology, the system enables sharing of this data with other interventional labs around the world via a secure Internet connection. With its unique capabilities, we anticipate that the Odyssey network will continue to establish a forum for defining clinical best practices across a broad spectrum of medical procedures.”

About Odyssey

The Odyssey portfolio of products provides an innovative information backbone for managing, controlling, recording and sharing procedures performed in interventional labs. The Odyssey Workstation standardizes data integration for magnetic and standard interventional labs by enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Through its proprietary data compression technology, the Odyssey enables the sharing of live and recorded procedure data via a laptop anywhere over a secure high speed Internet connection. Hospitals can also share procedures with other institutions using Odyssey Connect providing a forum for defining clinical best practices across a broad spectrum of medical procedures.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.

About Forward Looking Statements

This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Il Rosso e il Verde

Dal 12 luglio 2009.

Il Rosso e il Verde è un appuntamento soprattutto con me stesso. Il Rosso, sugli schermi dei computer, è il colore dei titoli azionari che perdono valore; il Verde è quello dei titoli che salgono.

Il Rosso e il Verde è un titolo che fa chiaramente il verso a Il Rosso e il Nero, celebre romanzo di Stendhal – la pagina di Wikipedia a esso dedicata vi offre tutte le interpretazioni simboliche legate alla scelta di tali colori. Ovviamente mi richiamo di conseguenza anche all’omonima rubrica di Alessando Fugnoli, attualmente pubblicata sul sito di Abaxbank .

Leggo molto e scrivo poco. Vorrei invece scrivere ciò che condenso dalle ore di lettura e di riflessione in merito all’economia e alla politica.

Son stato via due settimane in vacanza, ero quasi senza computer, solo al ritorno ho trovato questa notizia che riguarda Hansen:
Hansen Medical sees Q2 revenue lower than expected – Hansen Medical si aspetta un fatturato nel secondo trimestre più basso di quanto previsto.

Chi segue questo sito conosce da tempo la mia opinione su Hansen: penso che il titolo azionario di tale azienda farà peggio del mercato nel suo complesso (prendo a riferimento l’indice S&P 500).

Ho trovato molto spiritoso il commento pubblicato qui (in inglese).

L’azienda sostiene che il minor fatturato sarà dovuto alla congiuntura sfavorevole. Ma è chiaro, almeno a me, che Hansen ha giocato molto sul fatto di essere guidata da due dei fondatori di Intuitive Surgical (ISRG – azienda che ha ben altro presente e ben altro futuro), cioè Fred Moll e Rob Younge. Ma il prodotto dov’è?

Hedgemaven si è preso la briga di ascoltare la conferenza stampa e ce ne ha raccontato i punti salienti.
In sintesi, ecco il rapporto di Hedgemaven:
“In conferenza stampa i vertici parlano di “inesplicabile rallentamento delle decisioni d’acquisto” da parte dei clienti, a proposito della loro strumentazione, che secondo loro ha un miglior rapporto qualità/prezzo rispetto a quella di Stereotaxis.
Coloro che da tempo seguono queste due aziende sanno che il “miglior rapporto qualità/prezzo” non è altro che un minor costo dell’apparecchiatura Sensei di Hansen rispetto alla Niobe di Stereotaxis, ma questo è tutto, perché non si tiene conto del fatto che con Sensei il medico deve indossare le protezioni in piombo, con Niobe no; con Sensei il costo dei consumabili è più alto che con Niobe; Niobe ha un profilo di sicurezza enormemente superiore a Sensei; Sensei può essere usato solo nell’atrio sinistro, Niobe in tutte e quattro le camere cardiache; Sensei ancora è privo di approvazione della FDA e viene usato off-label (sebbene Fred Moll abbia detto che spera di avere l’approvazione per il trattamento della fibrillazione atriale durante il prossimo anno); i medici non usano i Sensei acquistati (chissà perché?!?).”


Creative Commons License
Questo/a opera è pubblicato sotto una Licenza Creative Commons.


Di Giancarlo Nicoli, Appiano Gentile, CO
Il presente articolo è stato scritto da Giancarlo Nicoli. Le informazioni qui contenute sono state ricavate da fonti, che Giancarlo Nicoli ha ritenuto affidabili. L’accuratezza e la completezza delle stesse non può essere in nessun modo garantita. La presente pubblicazione viene a pubblicata per meri fini di informazione ed illustrazione, non costituendo peraltro la stessa in alcun modo una proposta di conclusione di contratto o una sollecitazione all’acquisto o alla vendita di qualsiasi strumento finanziario. Il documento può essere riprodotto nella sua interezza. A tal proposito si chiede la cortesia di citare la fonte: www.scoprire.biz. La presente pubblicazione non si propone di sostituire il giudizio personale dei soggetti a cui si rivolge. Giancarlo Nicoli ha la facoltà di agire in base a/ovvero di servirsi di qualsiasi materiale sopra esposto e/o di qualsiasi informazione a cui tale materiale si ispira prima che lo stesso venga pubblicato e messo a disposizione della clientela.
Giancarlo Nicoli può occasionalmente assumere posizioni lunghe o corte nei summenzionati prodotti finanziari.
I link sono stati verificati e risultano funzionanti al momento della pubblicazione del presente articolo.

di Giancarlo Nicoli

Allo Hearth Rhytm 2009 va in mostra la leadership di mercato di Stereotaxis

Filed Under Stereotaxis | Comments Off on Allo Hearth Rhytm 2009 va in mostra la leadership di mercato di Stereotaxis

Traduzione e adattamento dall’inglese del comunicato stampa Stereotaxis di Phil Vardena.

Lunedì 11 maggio 2009

La Navigazione Magnetica da Remoto è ben presente nel programma HRS 2009.

St. Louis (USA). Stereotaxis, Inc. (Nasdaq: STXS), annuncia oggi che il programma del Hearth Rhythm 2009 contiene 21 podi e presentazioni di poster in cui in cui il suo sistema Niobe è o presentato o discusso per quanto riguarda il trattamento di aritmie cardiache complesse. Queste presentazioni includono nuovi dati di efficacia riguardanti l’uso di del catetere irrigato magnetico del partner di Stereotaxis, nei centri di Copenaghen e di Amburgo.

Xu Chen, dottore del Rigshospitalet di Copenaghen, presenterà “Risultati acuti e a lungo termine della navigazione magnetica da remoto per l’ablazione della fibrillazione atriale mediante un catetere irrigato magnetico” in occasione di una sessione con inizio alle ore 10.30 di venerdì 15 maggio,  nella Sala 162. Nella stessa sessione, Erik Weissner della Asklepios Klinik St. Georg di Amburgo presenterà “Isolamento della vena polmonare con navigazione da remoto utilizzando la seconda generazione – di 3,5 millimetri – del catetere irrigato magnetico”.

Inoltre, Tamas Szili-Torok, dottore all’Erasmus Medical Center di Rotterdam e Jinjin Wu, dottore del German Heart Center di Monaco di Baviera presenteranno allo stand Stereotaxis (n° 778)  le loro esperienze con il sistema Niobe di navigazione magnetica da remoto e il trattamento delle aritmie nei bambini. Queste presentazioni nello stand sono separati dalle conferenza di presentazione che vertono sullo stesso argomento.
[leggi tutto…]

di Giancarlo Nicoli

Stereotaxis annuncia i risultati del primo trimestre 2009

Filed Under Stereotaxis | Comments Off on Stereotaxis annuncia i risultati del primo trimestre 2009

Traduzione e adattamento dall’inglese del comunicato stampa Stereotaxis di Phil Vardena.

Giovedì 7 maggio 2009

Fatturato di 11,1 milioni di dollari, in aumento del 58% rispetto allo stesso trimestre dell’anno precedente

Le entrate ricorrenti raggiungono il nuovo massimo storico a 4,3 milioni di dollari

Margine lordo record del 69%

Diminuzione delle spese operative del 17%, riduzione della perdita d’esercizio del 46%.

St. Louis (USA). Stereotaxis, Inc. (Nasdaq: STXS), annuncia i risultati finanziari per il primo trimestre chiuso al 31 marzo 2009. Il fatturato del primo trimestre del 2009 è pari a $ 11,1 milioni, con un incremento di oltre il 58% rispetto ai $ 7,0 milioni riportati nello stesso periodo del 2008. L’azienda ha contabilizzato ricavi su cinque sistemi di navigazione magnetica Niobe (R) e cinque sistemi Odyssey (TM) per complessivi 6,9 milioni di dollari, mentre i ricavi da strumenti monouso, servizi e accessori hanno segnato un nuovo record a $ 4,3 milioni, un aumento del 61% rispetto allo stesso periodo del 2008. Gli ordini chiusi nel corso del primo trimestre, di sistemi Niobe e Odyssey, sono pari a $ 8,8 milioni,  il portafoglio ordini totale è di $ 67 milioni. Le spese di funzionamento dell’azienda sono scese a $ 14,8 milioni, una diminuzione del 17% rispetto al primo trimestre del 2008.

Michael P. Kaminski, Presidente e Chief Executive Officer, ha dichiarato: “Durante il primo trimestre, abbiamo dimostrato una forte crescita dei ricavi, margini eccezionalmente forti su tutti i nostri prodotti, e una significativa crescita delle entrate ricorrenti, derivanti principalmente dal lancio del catetere irrigato magnetico. Inoltre, l’azienda continua a concentrarsi sulle principali iniziative e guidare i efficaci processi interni che diano luogo a un miglioramento delle spese operative rispetto all’anno scorso.
[leggi tutto…]

di Giancarlo Nicoli

Stereotaxis: nuovi prodotti in mostra al Boston Atrial Fibrillation Symposium

Filed Under Stereotaxis | Comments Off on Stereotaxis: nuovi prodotti in mostra al Boston Atrial Fibrillation Symposium

Traduzione e adattamento dall’inglese del comunicato stampa Stereotaxis di Phil Vardena.

Mercoledì 14 gennaio 2009

In mostra da Stereotaxis, allo stand 917 del Boston Atrial Fibrillation Symposium, tre nuovi prodotti per le ablazioni mediante navigazione magnetica.

St. Louis (USA). Stereotaxis, Inc. (Nasdaq: STXS), annuncia che al Boston Atrial Fibrillation Symposium, saranno in vetrina tre nuovi prodotti da usare nelle ablazioni mediante navigazione magnetica da remoto; prodotti che l’azienda ritiene miglioreranno l’efficienza, le prestazioni e la versatilità dei suoi sistemi di navigazione magnetica Niobe (R).

Stereotaxis esporrà, allo stand 917, la sua nuova piattaforma software, Navigant 3.0, con il sistema QuikCAS (TM) Cardiodrive (R) per il miglioramento del controllo remoto del catetere e un miglioramento del flusso di lavoro del laboratorio EP [elettrofisiologia], e il suo catetere irrigato magnetico, sviluppato dal proprio partner industriale, che è ora disponibile in Europa.
[leggi tutto…]

Next Page →

%d bloggers like this: